Its also associated with a heightened risk of specific cancer types
Overall, the incidence of adverse events is generally higher in diabetes patients compared to obesity patients
Saxenda a higher-dose daily liraglutide formulation Wegovy a higher-dose weekly semaglutide formulation Zepbound the weight-loss formulation of tirzepatide These medications are typically approved for adults with obesity, or for those who are overweight with additional health conditions such as high blood pressure, abnormal cholesterol, or sleep apnoea
Specifically, tirzepatide prescriptions increased from 0.7% in 2022 to 2.8% in 2025, whereas semaglutide prescriptions decreased from 4.2% in 2022 to 2.1% in 2025
Biochem Pharmacol 230(Pt 3):116623 Nakanishi N, Osuka S, Kono T et al (2023) Upregulated ribosomal pathway impairs follicle development in a polycystic ovary syndrome mouse model: differential gene expression analysis of oocytes